Sacituzumab govitecan (SG) is a novel ADC that works by binding Trop-2 which is highly expressed in the majority of TNBCs and delivers the SN-38 payload drug to the cancer cells with a hydrolysable linker [19]. The gene discussed is TACSTD2; the disease is cancer.